Jagsonpal Pharmaceuticals completed the acquisition of India & Bhutan business of Yash Pharma Laboratories along with the brands and associated trademark. The acquired business shall be consolidated with the Company`s financials with effect from 01 June 2024.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 20 May 2024, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 100%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals declined 36.61% to Rs 3.55 crore in the quarter ended March 2024 as against Rs 5.60 crore during the previous quarter ended March 2023. Sales declined 21.57% to Rs 43.49 crore in the quarter ended March 2024 as against Rs 55.45 crore during the previous quarter ended March 2023.For the full year,net profit declined 15.94% to Rs 22.46 crore in the year ended March 2024 as against Rs 26.72 crore during the previous year ended March 2023. Sales declined 11.83% to Rs 208.70 crore in the year ended March 2024 as against Rs 236.71 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales43.4955.45 -22 208.70236.71 -12 OPM %6.129.81 -11.0514.43 - PBDT4.937.80 -37 31.5339.48 -20 PBT4.537.32 -38 29.8738.27 -22 NP3.555.60 -37 22.4626.72 -16 Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals declined 49.17% to Rs 3.96 crore in the quarter ended December 2023 as against Rs 7.79 crore during the previous quarter ended December 2022. Sales declined 21.43% to Rs 47.25 crore in the quarter ended December 2023 as against Rs 60.14 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales47.2560.14 -21 OPM %7.1714.37 - PBDT5.6810.20 -44 PBT5.279.87 -47 NP3.967.79 -49 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 February 2024.Powered by Capital Market - Live News